3 Dividend Stocks That Are No-Brainer Buys Heading Into the Second Half of 2026

The article highlights three high-yield income plays into 2H 2026: Novo Nordisk at ~3.5% yield (but pressured by falling GLP-1 pricing despite faster Wegovy pill uptake), Realty Income at ~5% yield with a 31-year annual dividend streak, and Enterprise Products Partners at ~5.9% yield with 1.7x coverage of its distribution. It argues Novo can regain GLP-1 share as volume offsets lower prices, while Realty’s net-lease model supports durability and Enterprise’s toll-taker midstream fees reduce commodity oil-price risk. Overall, the tone is cautiously constructive: attractive yields, but Novo faces near-term pricing headwinds.

Analysis

The market is likely over-optimizing for yield and underweighting balance-sheet quality and cash-flow durability. EPD is the cleanest expression of that theme: if capital rotates toward fee-based midstream as oil normalizes, the multiple should hold up better than upstream energy even if the commodity tape fades. The second-order loser is the more commodity-sensitive E&P basket; the winner is infrastructure with contracted throughput and less earnings volatility.

NVO is more interesting as a margin-versus-volume story than as a dividend story. If oral adoption is real, the market may be underestimating the mix shift toward lower-friction prescribing, but it also risks compressing gross margin and keeping the stock cheap for longer if volume does not scale fast enough. Near term, the key catalyst is not the product announcement but weekly prescription/trade-channel data; if that fails to inflect, the “cheap contrarian” setup can become a value trap.

O remains a rate proxy more than a real estate story. In a falling-rate regime it can work as a bond substitute, but if the market starts to reprice long-end yields higher, the dividend premium is vulnerable to multiple compression even if the payout is intact. The key second-order effect is capital rotation within REITs: low-growth net lease names should lag higher-growth or data-center exposed landlords if growth expectations widen.

Consensus may be missing that these are three different risks wrapped in the same yield narrative: duration risk for O, execution risk for NVO, and low-beta cash-flow resilience for EPD. There is no obvious broad basket trade here unless you separate rate sensitivity from operating leverage. The cleanest falsifier is a sustained move higher in rates, weaker GLP-1 prescription acceleration, or a drop in EPD volume/DCF coverage below the current comfort zone.

Key Decisions for Investors

• Prefer EPD over XLE for the next 3-6 months: long EPD / short XLE if the base case is moderating oil prices and continued demand for fee-based infrastructure. Risk: a sharp commodity spike would favor XLE beta; thesis is falsified if EPD distribution coverage deteriorates or volume growth stalls.
• Initiate only a small starter long in NVO, sized as a catalyst watch rather than a conviction trade. Best entry is after confirmation of oral GLP-1 uptake in prescription data; use a 1-3 month horizon and avoid paying up before the market sees real volume acceleration. Falsify if gross-to-net pressure rises without offsetting script growth.
• Use O as a rates hedge, not a pure alpha idea: long O only if the market is pricing an extended decline in long yields over the next 6-12 months. If 10-year Treasury yields rebound, expect REIT multiple compression to outweigh dividend support.
• Pair trade idea: long EPD / short a more commodity-sensitive energy proxy or upstream E&P basket on any oil-strength rally. This expresses the view that infrastructure cash flows are more durable than production-linked earnings once the market looks past the headline energy move.